CUCCI, Marie Angele
 Distribuzione geografica
Continente #
NA - Nord America 2.196
EU - Europa 1.656
AS - Asia 698
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 6
SA - Sud America 4
Totale 4.628
Nazione #
US - Stati Uniti d'America 2.166
CN - Cina 406
IT - Italia 281
IE - Irlanda 209
UA - Ucraina 196
GB - Regno Unito 192
SE - Svezia 181
DE - Germania 153
FI - Finlandia 120
FR - Francia 114
KR - Corea 104
PL - Polonia 66
AT - Austria 56
VN - Vietnam 48
IN - India 47
SG - Singapore 33
SN - Senegal 28
CA - Canada 25
GR - Grecia 18
HK - Hong Kong 15
MU - Mauritius 15
NL - Olanda 15
BE - Belgio 12
EU - Europa 11
JP - Giappone 11
ET - Etiopia 10
RU - Federazione Russa 10
IR - Iran 8
TR - Turchia 7
ES - Italia 5
MX - Messico 5
NZ - Nuova Zelanda 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
PT - Portogallo 4
UZ - Uzbekistan 4
HR - Croazia 3
IQ - Iraq 3
RO - Romania 3
BG - Bulgaria 2
EE - Estonia 2
EG - Egitto 2
IL - Israele 2
NO - Norvegia 2
TW - Taiwan 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BR - Brasile 1
BY - Bielorussia 1
DZ - Algeria 1
HU - Ungheria 1
ID - Indonesia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
NG - Nigeria 1
PH - Filippine 1
Totale 4.628
Città #
Chandler 391
Dublin 206
Beijing 200
Fremont 139
Ann Arbor 120
Fairfield 100
Ashburn 98
Jacksonville 97
Torino 91
Houston 89
Nyköping 88
Medford 87
Dearborn 86
Princeton 68
Warsaw 65
Villeurbanne 57
Vienna 55
Woodbridge 55
Wilmington 45
Milan 38
Dong Ket 37
Cambridge 34
Seattle 30
Turin 29
Verona 27
Singapore 23
Pisa 18
Redwood City 17
San Diego 16
Shanghai 16
Boston 15
Hefei 14
Guangzhou 12
Norwalk 12
Washington 12
Falls Church 11
Hebei 10
Kunming 10
Wuhan 10
Athens 9
Boardman 9
Brussels 9
Helsinki 9
Nanjing 9
Xian 9
Lachine 8
Frankfurt am Main 7
Jinan 7
Los Angeles 7
Rome 7
Hangzhou 6
Nanchang 6
Shenyang 6
Toronto 6
Amsterdam 5
Central District 5
Gloucester 5
Guiyang 5
Lucknow 5
Pune 5
Redmond 5
Valdagno 5
Central 4
Düsseldorf 4
Hong Kong 4
Hyderabad 4
London 4
New York 4
Addis Ababa 3
Ahmedabad 3
Baotou 3
Chongqing 3
Coral Gables 3
Cuneo 3
Edinburgh 3
Glasgow 3
Guwahati 3
Montreal 3
Münster 3
Napoli 3
Nürnberg 3
Prague 3
Taizhou 3
Tianjin 3
Upper Marlboro 3
Ankara 2
Ariano Irpino 2
Bengbu 2
Berloz 2
Cagliari 2
Castellabate 2
Chang-hua 2
Chuncheon 2
Dallas 2
Delhi 2
Duncan 2
Durham 2
Fredericton 2
Fuzhou 2
Gravina In Puglia 2
Totale 2.787
Nome #
Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells 251
Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A 236
Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression 187
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 176
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 165
The Potential Therapeutic Target Nrf2 in Childhood Brain Tumors 145
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 142
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 111
Treatment response to interferon beta: Biological (MxA protein or IL-10 mRNA level) or MRI indicators? 105
Lipid peroxidation-derived aldehydes, 4-hydroxynonenal and malondialdehyde in aging-related disorders 95
Glutathione-responsive cyclodextrin-nanosponges as drug delivery systems for doxorubicin: Evaluation of toxicity and transport mechanisms in the liver 94
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 86
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 82
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 81
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation 80
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b 79
Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role 78
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 75
Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy 74
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 74
Carbosilane dendrimers loaded with sirna targeting nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells 74
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. 73
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). 73
Is the combination of different treatment responseindicators useful to identify patients with a sub-optimal response to interferon beta? 73
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 71
La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b 70
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a. 69
Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells 67
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 66
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. 65
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a 65
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 64
The OPTimization of interferon for MS (OPTIMS) study. A multicenter trial comparing two different doses (250 and 375 mcg) of IFN beta-1b 59
Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients. 58
Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism 57
Oxidative stress-related mechanisms in melanoma and in the acquired resistance to targeted therapies 57
Using biological (mxa protein or il-10 mrna level) or mri indicators for assessing treatment response to interferon-beta 56
High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose 56
Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma 53
Mxa protein and interleukin-10 (il-10) leukocyte production and anti-ifn neutralizing antibody(nab) occurrence in relapsing remitting multiple sclerosis (rrms) patients treated with different doses of interferon (ifn) beta- 1b 51
Is it possible to reduce the dose of interferon (IFN) beta in MS patients with a prolonged MRI-confirmed absence of disease activity? 51
To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved. 50
Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a 50
Mxa protein in ms patients treated with different doses of ifn beta-1b (the optims study): correlation with treatment response, ifn beta dose, and neutralizing antibodies (nab)occurrence 49
NAB titre in patients treated with different doses of ifn beta-1b: preliminary results from the optims study. 47
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial 46
High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study 44
Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response 41
Mxa protein, interleukin-10 and neutralising antibody in MS patients treated with different doses of Interferon-Beta-1b 40
Secondary progressive (sp) ms: immunological effects of intravenous immunoglobuln g (ivig) therapy 40
Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells 40
Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study. 39
Mxa protein, interleukin-10 (il-10) and neutralizing antibody (nab) in relapsing- remitting (rr) multiple sclerosis (ms) patients treated with different doses of inteferon (ifn) beta- 1b. 38
Interferon beta-1b 500 mcg every-other-day, subcutaneously in ms patients. Tolerability, clinical and mri results after one year of treatment 37
High-dose (375 mcg) interferon beta-1b treatment of multiple sclerosis and neutralising antibodies. Long-term follow-up 37
IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment 37
Mxa protein: correlation with magnetic resonance imaging response in relapsing-remitting multiple sclerosis patients treated with two different ifn beta doses 36
Interferon beta-1b 500 mcg every-other-day in ms patients. Clinical and mri results 35
MX protein and neutralizing interferon antibodies in relapsing remitting multiple sclerosis patients treated with interferon beta-1b: correlation with clinical and mri efficacy 35
PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE MRNA BLOOD LEVEL IN MULTIPLE SCLEROSIS IS RELATED TO TREATMENT RESPONSE AND INTERFERON-BETA DOSE 35
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study). 34
Real-time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors, in patients treated with ifn beta 1b: correlation with mri response and evaluation of a prognostic marker in ms. 34
Looking for treatment response indicator. real- time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors in Multiple Sclerosis patients treated with ifn beta 1b: correlation with mri response 31
Long-term evaluation of safety and efficacy of mitoxantrone therapy in secondary progressive Multiple Sclerosis patients. 31
Indicators of treatment response to interferon beta in ms. mxa protein, il-10 mrna or mri? 30
MRNA levels of cytokines, chemokines and chemokine receptors as indicator of treatment response in Multiple Sclerosis patients treated with interferon-beta 1b 30
Nrf2 role in the BRAFi/MEKi acquired resistance in melanoma 28
Mitoxantrone safety in secondary progressive Multiple Sclerosis patients 27
Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma 12
Nrf2, YAP, antioxidant potential, and cancer 12
Surface Functionalised Parenteral Nanoemulsions for Active and Homotypic Targeting to Melanoma 9
Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle 7
Totale 4.805
Categoria #
all - tutte 14.469
article - articoli 0
book - libri 0
conference - conferenze 8.541
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.010


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201936 0 0 0 0 0 0 0 0 0 0 0 36
2019/2020694 18 17 48 65 59 97 90 46 89 80 36 49
2020/2021628 78 50 61 33 36 39 33 27 103 35 51 82
2021/2022730 24 17 19 43 35 42 28 35 48 81 158 200
2022/20231.082 109 93 19 141 83 264 70 83 105 24 55 36
2023/2024451 51 73 34 54 36 66 17 24 6 31 51 8
Totale 4.805